Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market Growth driven by increased adoption of targeted therapies
Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market |
Market Overview:
Relapsed Or Refractory Diffuse Large B Cell Lymphoma
(R/R DLBCL) is an aggressive fast-growing type of non-Hodgkin's lymphoma (NHL)
cancer that generally affects immune system cells called B cells. DLBCL can
occur at any age but is most common in older adults. Novel targeted therapies
like chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies
and antibody-drug conjugates are revolutionizing the treatment of R/R DLBCL.
These advanced therapies are offering new hope to patients by increasing
survival rates.
Market key trends:
One of the key trends in the R/R DLBCL market is the increasing adoption of
CAR T-cell therapies. CAR T-cell therapy is an innovative new approach to
treating R/R DLBCL through the use of genetically engineered T-cells. Drugs
like Kymriah and Yescarta have proven highly effective in treating certain
patients with relapsed or refractory forms of large B-cell lymphoma. The FDA
approval of such novel therapies has shifted the treatment paradigm for R/R
DLBCL patients. Advancements in immunotherapy and precision medicine will
likely drive further innovations in treating this aggressive blood cancer going
forward.
Porter’s Analysis
Threat of new entrants: The biopharmaceutical industry requires high R&D
investment and regulatory approvals which poses significant entry barriers for
new entrants.
Bargaining power of buyers: The bargaining power of buyers is moderate as
treatment options for R/R DLBCL are limited and patients have constrained
treatment choices.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to
availability of alternative treatment options and dependency of key players on
suppliers for raw materials and services.
Threat of new substitutes: Threat of substitutes is low as there are limited
treatment alternatives available for R/R DLBCL.
Competitive rivalry: The market witnesses high competitive rivalry among
existing players due to their focus on developing novel therapeutics.
Key Takeaways
The global Relapsed
Or Refractory Diffuse Large B Cell Lymphoma Market is expected to
witness high growth, exhibiting a CAGR of 4.3% over the forecast period, due to
increasing approvals of novel treatments.
The North America region is expected to dominate the market throughout the
forecast period due to growing prevalence of lymphoma in the region and rapid
adoption of advanced treatment options. The Asia Pacific region is anticipated
to exhibit the fastest growth rate over the next few years owing to rising
healthcare investments and improving access to treatment.
Key players operating in the relapsed or refractory diffuse large B cell
lymphoma market are MorphoSys U.S. Inc., Bristol-Myers Squibb Company,
Karyopharm Therapeutics, Hoffmann-La Roche AG, Merck & Co., Inc., Gilead
Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine
Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer
Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle
Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation.
Read
More:
https://www.dailyprbulletin.com/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market/
Comments
Post a Comment